[{"orgOrder":0,"company":"St. Jude Children","sponsor":"BioLineRx","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Motixafortide","moa":"C-X-C chemokine receptor type 4","graph1":"Genetic Disease","graph2":"Phase I","graph3":"St. Jude Children","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"St. Jude Children \/ BioLineRx","highestDevelopmentStatusID":"6","companyTruncated":"St. Jude Children \/ BioLineRx"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Celerion","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"ISRAEL","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Motixafortide","moa":"C-X-C chemokine receptor type 4","graph1":"Undisclosed","graph2":"Phase I","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioLineRx \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"BioLineRx \/ Celerion"},{"orgOrder":0,"company":"Gloria Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Motixafortide","moa":"C-X-C chemokine receptor type 4","graph1":"Oncology","graph2":"Phase III","graph3":"Gloria Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gloria Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Gloria Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Blackrock","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide, Unconjugated","year":"2024","type":"Financing","leadProduct":"Motixafortide","moa":"||C-X-C chemokine receptor type 4","graph1":"Oncology","graph2":"Approved FDF","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioLineRx \/ Blackrock","highestDevelopmentStatusID":"15","companyTruncated":"BioLineRx \/ Blackrock"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Motixafortide","moa":"||C-X-C chemokine receptor type 4","graph1":"Oncology","graph2":"Approved FDF","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioLineRx \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"BioLineRx \/ Undisclosed"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Jonestrading Institutional Services","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide, Unconjugated","year":"2024","type":"Public Offering","leadProduct":"Motixafortide","moa":"||C-X-C chemokine receptor type 4","graph1":"Oncology","graph2":"Approved FDF","graph3":"BioLineRx","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"BioLineRx \/ Jonestrading Institutional Services","highestDevelopmentStatusID":"15","companyTruncated":"BioLineRx \/ Jonestrading Institutional Services"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Motixafortide","moa":"||C-X-C chemokine receptor type 4","graph1":"Oncology","graph2":"Approved FDF","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioLineRx \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"BioLineRx \/ Undisclosed"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Washington University School of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Peptide, Unconjugated","year":"2023","type":"Collaboration","leadProduct":"Motixafortide","moa":"||C-X-C chemokine receptor type 4","graph1":"Genetic Disease","graph2":"Phase I","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioLineRx \/ Washington University School of Medicine","highestDevelopmentStatusID":"6","companyTruncated":"BioLineRx \/ Washington University School of Medicine"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Ayrmid","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide, Unconjugated","year":"2024","type":"Licensing Agreement","leadProduct":"Motixafortide","moa":"||C-X-C chemokine receptor type 4","graph1":"Oncology","graph2":"Approved FDF","graph3":"BioLineRx","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Injection","sponsorNew":"BioLineRx \/ Ayrmid","highestDevelopmentStatusID":"15","companyTruncated":"BioLineRx \/ Ayrmid"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Gloria Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide, Unconjugated","year":"2023","type":"Licensing Agreement","leadProduct":"Motixafortide","moa":"||C-X-C chemokine receptor type 4","graph1":"Oncology","graph2":"Approved FDF","graph3":"BioLineRx","amount2":0.28000000000000003,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.28000000000000003,"dosageForm":"Injection","sponsorNew":"BioLineRx \/ Gloria Biosciences","highestDevelopmentStatusID":"15","companyTruncated":"BioLineRx \/ Gloria Biosciences"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Motixafortide","moa":"||C-X-C chemokine receptor type 4","graph1":"Oncology","graph2":"Approved FDF","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioLineRx \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"BioLineRx \/ Undisclosed"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Motixafortide","moa":"||C-X-C chemokine receptor type 4","graph1":"Oncology","graph2":"Approved FDF","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioLineRx \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"BioLineRx \/ Undisclosed"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Motixafortide","moa":"||C-X-C chemokine receptor type 4","graph1":"Oncology","graph2":"Approved FDF","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioLineRx \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"BioLineRx \/ Undisclosed"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Motixafortide","moa":"||C-X-C chemokine receptor type 4","graph1":"Oncology","graph2":"Approved FDF","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioLineRx \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"BioLineRx \/ Undisclosed"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Motixafortide","moa":"||C-X-C chemokine receptor type 4","graph1":"Oncology","graph2":"Approved FDF","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioLineRx \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"BioLineRx \/ Undisclosed"},{"orgOrder":0,"company":"BioLineRx","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide, Unconjugated","year":"2025","type":"Public Offering","leadProduct":"Motixafortide","moa":"||C-X-C chemokine receptor type 4","graph1":"Oncology","graph2":"Phase II","graph3":"BioLineRx","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"BioLineRx \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"BioLineRx \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Highbridge Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide, Unconjugated","year":"2024","type":"Financing","leadProduct":"Motixafortide","moa":"||C-X-C chemokine receptor type 4","graph1":"Oncology","graph2":"Phase II","graph3":"BioLineRx","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"BioLineRx \/ Highbridge Capital Management","highestDevelopmentStatusID":"8","companyTruncated":"BioLineRx \/ Highbridge Capital Management"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Motixafortide","moa":"||C-X-C chemokine receptor type 4","graph1":"Oncology","graph2":"Phase II","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioLineRx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioLineRx \/ Undisclosed"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Motixafortide","moa":"||C-X-C chemokine receptor type 4","graph1":"Oncology","graph2":"Phase II","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioLineRx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioLineRx \/ Undisclosed"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Motixafortide","moa":"||C-X-C chemokine receptor type 4","graph1":"Oncology","graph2":"Phase II","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioLineRx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioLineRx \/ Undisclosed"},{"orgOrder":0,"company":"BioLineRx","sponsor":"GenFleet Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide, Unconjugated","year":"2022","type":"Collaboration","leadProduct":"Motixafortide","moa":"||C-X-C chemokine receptor type 4","graph1":"Oncology","graph2":"Phase II","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioLineRx \/ GenFleet Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"BioLineRx \/ GenFleet Therapeutics"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Motixafortide","moa":"||C-X-C chemokine receptor type 4","graph1":"Oncology","graph2":"Phase II","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioLineRx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioLineRx \/ Undisclosed"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Motixafortide","moa":"||C-X-C chemokine receptor type 4","graph1":"Oncology","graph2":"Phase II","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioLineRx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioLineRx \/ Undisclosed"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Motixafortide","moa":"||C-X-C chemokine receptor type 4","graph1":"Oncology","graph2":"Phase II","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioLineRx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioLineRx \/ Undisclosed"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Motixafortide","moa":"||C-X-C chemokine receptor type 4","graph1":"Oncology","graph2":"Phase II","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioLineRx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioLineRx \/ Undisclosed"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Motixafortide","moa":"||C-X-C chemokine receptor type 4","graph1":"Oncology","graph2":"Phase II","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioLineRx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioLineRx \/ Undisclosed"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Motixafortide","moa":"||C-X-C chemokine receptor type 4","graph1":"Oncology","graph2":"Phase II","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioLineRx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioLineRx \/ Undisclosed"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Motixafortide","moa":"||C-X-C chemokine receptor type 4","graph1":"Genetic Disease","graph2":"Phase I","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioLineRx \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BioLineRx \/ Undisclosed"},{"orgOrder":0,"company":"BioLineRx","sponsor":"St. Jude Children\u2019s Research Hospital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Peptide, Unconjugated","year":"2024","type":"Agreement","leadProduct":"Motixafortide","moa":"C-X-C chemokine receptor type 4","graph1":"Genetic Disease","graph2":"Phase I","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioLineRx \/ St. Jude Children\u2019s Research Hospital","highestDevelopmentStatusID":"6","companyTruncated":"BioLineRx \/ St. Jude Children\u2019s Research Hospital"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"BioLineRx | Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Motixafortide","moa":"C-X-C chemokine receptor type 4","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Washington University School of Medicine \/ BioLineRx | Biogen","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ BioLineRx | Biogen"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"BioLineRx | Arvrmid Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Motixafortide","moa":"C-X-C chemokine receptor type 4","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Washington University School of Medicine \/ BioLineRx | Arvrmid Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ BioLineRx | Arvrmid Pharma"},{"orgOrder":0,"company":"Gulam Manji","sponsor":"Regeneron Pharmaceuticals | BioLineRx","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Motixafortide","moa":"C-X-C chemokine receptor type 4","graph1":"Oncology","graph2":"Phase II","graph3":"Gulam Manji","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gulam Manji \/ Regeneron Pharmaceuticals | BioLineRx","highestDevelopmentStatusID":"8","companyTruncated":"Gulam Manji \/ Regeneron Pharmaceuticals | BioLineRx"}]
Find Clinical Drug Pipeline Developments & Deals for Motixafortide
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
